Taysha Gene Therapies
TSHA
107 hedge funds and large institutions have $354M invested in Taysha Gene Therapies in 2024 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 29 increasing their positions, 21 reducing their positions, and 38 closing their positions.
110% more call options, than puts
Call options by funds: $208K | Put options by funds: $99K
38% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 21
3.58% more ownership
Funds ownership: 74.96% → 78.53% (+3.6%)
5% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 38
2% less funds holding
Funds holding: 109 → 107 (-2)
12% less capital invested
Capital invested by funds: $402M → $354M (-$47.9M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$26.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$8.67M |
| 3 |
JP Morgan Chase
New York
|
+$8.35M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$7.38M |
| 5 |
Morgan Stanley
New York
|
+$6.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$8.13M |
| 2 |
EP
Eversept Partners
New York
|
-$6.67M |
| 3 |
CAC
Cowen and Company
New York
|
-$4.45M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.44M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.19M |
TSHA Hedge Fund Activity: Q2 2024 in Review
107 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q2 2024, worth a combined $354M — down 12% from $402M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of TSHA and 36 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 29 added.
The largest buyer was BlackRock, adding an estimated $26.6M. The largest seller was Millennium Management, cutting an estimated $8.13M.
- 107 institutional investors held Taysha Gene Therapies (TSHA) as of Q2 2024, down from 109 in Q1 2024.
- Funds reported $354M of Taysha Gene Therapies stock for Q2 2024, down 12% quarter-over-quarter.
- 36 funds opened new Taysha Gene Therapies positions in Q2 2024 and 38 closed out, a net change of -2 holders.
- The largest Taysha Gene Therapies buyer in Q2 2024 was BlackRock, an estimated $26.6M added.
- The largest Taysha Gene Therapies seller in Q2 2024 was Millennium Management, an estimated $8.13M sold.
Based on aggregated 13F filings for Q2 2024.